Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1921. Platinum containing regimens for metastatic breast cancer.

Platinum containing regimens for metastatic breast cancer. BACKGROUND: Studies have reported high tumour response rates for platinum-containing regimens in the treatment of women with metastatic breast cancer. OBJECTIVES: To identify and review the evidence from randomised trials comparing platinum-containing chemotherapy regimens with regimens not containing platinum in the management of women with metastatic breast cancer. SEARCH STRATEGY: The specialised register maintained by the editorial (...) base of the Cochrane Breast Cancer Group was searched on 2nd May 2003 using the codes for "advanced breast cancer", "chemotherapy". Details of the search strategy applied to create the register, and the procedure used to code references, are described in the Cochrane Breast Cancer Group module on The Cochrane Library. SELECTION CRITERIA: Randomised trials comparing platinum-containing chemotherapy regimens with regimens not containing platinum in women with metastatic breast cancer. DATA COLLECTION

Cochrane2004

1922. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study.

Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. CONTEXT: Women who are physically active have a decreased risk for breast cancer, but the types, amounts, and timing of activity needed are unknown. OBJECTIVE: To prospectively examine the association between current and past recreational physical activity and incidence of breast cancer in postmenopausal women. DESIGN, SETTING, AND PATIENTS: Prospective cohort study (...) in 74 171 women aged 50 to 79 years who were recruited by 40 US clinical centers from 1993 through 1998. MAIN OUTCOME MEASURE: Incident invasive and in situ breast cancer. RESULTS: We documented 1780 newly diagnosed cases of breast cancer over a mean follow-up of 4.7 years. Compared with less active women, women who engaged in regular strenuous physical activity at age 35 years had a 14% decreased risk of breast cancer (relative risk [RR], 0.86; 95% confidence interval [CI], 0.78-0.95). Similar

JAMA2003

1923. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both.

Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. CONTEXT: Defects in X-chromosome inactivation distort sex ratio in mice. The BRCA1 gene is also involved in X-chromosome inactivation, suggesting the possibility that some sex-ratio distortion may be associated with BRCA1-related human cancer syndromes. OBJECTIVE: To determine whether BRCA1 mutations are associated with distortion of the sex ratio (...) of births in families with breast cancer, ovarian cancer, or both. DESIGN AND SETTING: Analysis of germline mutations in participants from Spain who had been screened for BRCA between 1998 and 2002. PARTICIPANTS: Sixty-eight families with at least 3 breast cancer cases or ovarian cancer cases, or both types of cancer in 2 generations (germline mutations: BRCA1, n = 17; BRCA2, n = 15; and BRCA unrelated, n = 36). An average of 4 relatives per family were tested for the corresponding BRCA mutation. MAIN

JAMA2003

1924. Breast cancer and hormone-replacement therapy in the Million Women Study.

Breast cancer and hormone-replacement therapy in the Million Women Study. BACKGROUND: Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer. The Million Women Study was set up to investigate the effects of specific types of HRT on incident and fatal breast cancer. METHODS: 1084110 UK women aged 50-64 years were recruited into the Million Women Study between 1996 and 2001, provided information about their use of HRT and other personal details, and were (...) followed up for cancer incidence and death. FINDINGS: Half the women had used HRT; 9364 incident invasive breast cancers and 637 breast cancer deaths were registered after an average of 2.6 and 4.1 years of follow-up, respectively. Current users of HRT at recruitment were more likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-1.75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Past users of HRT were, however, not at an increased risk of incident

Lancet2003

1925. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. BACKGROUND: Systemic chemotherapy for operable breast cancer substantially decreases the risk of death. Patients often have de novo resistance or incomplete response to docetaxel, one of the most active agents in this disease. We postulated that gene expression profiles of the primary breast cancer can predict the response to docetaxel. METHODS: We took core biopsy samples from (...) primary breast tumours in 24 patients before treatment and then assessed tumour response to neoadjuvant docetaxel (four cycles, 100 mg/m2 daily for 3 weeks) by cDNA analysis of RNA extracted from biopsy samples using HgU95-Av2 GeneChip. FINDINGS: From the core biopsy samples, we extracted sufficient total RNA (3-6 microg) for cDNA array analysis using HgU95-Av2 GeneChip. Differential patterns of expression of 92 genes correlated with docetaxel response (p=0.001). Sensitive tumours had higher

Lancet2003

1926. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.

Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. CONTEXT: Second cancer is the leading cause of death in long-term survivors of Hodgkin disease (HD), with exceptionally high risks of breast cancer among women treated at a young age. Quantitative associations between radiotherapy dose delivered to the breast and administered chemotherapy have not been reported to date in large series, nor has the influence of ovarian exposures on subsequent risk (...) . OBJECTIVE: To quantify the long-term risk of breast cancer associated with use of radiotherapy and chemotherapy to treat young women with HD. DESIGN, SETTING, AND SUBJECTS: Matched case-control study of breast cancer within a cohort of 3817 female 1-year survivors of HD diagnosed at age 30 years or younger, between January 1, 1965, and December 31, 1994, and within 6 population-based cancer registries. The study was conducted March 1, 1996, through September 30, 1998. MAIN OUTCOME MEASURES: Relative

JAMA2003

1927. Are imprecise methods obscuring a relation between fat and breast cancer?

Are imprecise methods obscuring a relation between fat and breast cancer? Pooled analyses of cohort studies show no relation between fat intake and breast-cancer risk. However, food-frequency questionnaire (FFQ) methods used in these studies are prone to measurement error. We assessed diet with an FFQ and a detailed 7-day food diary in 13070 women between 1993 and 1997. We compared 168 breast-cancer cases incident by 2000 with four matched controls. Risk of breast cancer was associated (...) with saturated-fat intake measured with the food diary (hazard ratio 1.22 [95% CI 1.06-1.40], p=0.005, per quintile increase in energy-adjusted fat intake), but not with saturated fat measured with the FFQ (1.10 [0.94-1.29], p=0.23). Dietary measurement error might explain the absence of a significant association between dietary fat and breast-cancer risk in cohort studies.

Lancet2003

1928. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. CONTEXT: Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking. OBJECTIVE: To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status. DESIGN (...) : Population-based case-control study. SETTING: Three counties in western Washington State. PARTICIPANTS: Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases

JAMA2003

1929. Puberty and genetic susceptibility to breast cancer in a case-control study in twins.

Puberty and genetic susceptibility to breast cancer in a case-control study in twins. BACKGROUND: Breast cancer is thought to result from excessive cumulative exposure to ovarian hormones. Different predictors of hereditary and sporadic breast cancer suggest different pathogenic mechanisms. Affected twin pairs may help to illustrate such differences. METHODS: We obtained information from 1811 pairs of female twins, one or both of whom had breast cancer. The pairs were stratified according (...) to concordance or discordance for breast cancer, zygosity, the presence or absence of a family history of breast cancer, and the presence of bilateral or unilateral disease. Disease-concordant monozygotic pairs were assumed to have a higher genetic susceptibility than other subgroups of pairs. Paired twins were compared with respect to age at puberty and other factors. We calculated adjusted odds ratios for the diagnosis of breast cancer when only one twin was affected and for the first of the two diagnoses

NEJM2003

1930. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer.

Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. In an anecdotal report, complete resolution of chemotherapy-induced nausea was seen in a patient with breast cancer, after she was placed on the anticonvulsant gabapentin. On this basis, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other chemotherapy treatment in nine patients with breast cancer. Six of the nine reported at least a three-point improvement in peak

Lancet2003

1931. Gene expression predictors of breast cancer outcomes.

Gene expression predictors of breast cancer outcomes. BACKGROUND: Correlation of risk factors with genomic data promises to provide specific treatment for individual patients, and needs interpretation of complex, multivariate patterns in gene expression data, as well as assessment of their ability to improve clinical predictions. We aimed to predict nodal metastatic states and relapse for breast cancer patients. METHODS: We analysed DNA microarray data from samples of primary breast tumours (...) different biological processes underlying these two characteristics of breast cancer. Initial external validation came from similarly accurate predictions of nodal status of a small sample in a distinct population. INTERPRETATION: Multiple aggregate measures of profiles of gene expression define valuable predictive associations with lymph node metastasis and disease recurrence for individual patients. Gene expression data have the potential to aid accurate, individualised, prognosis. Importantly

Lancet2003

1932. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening.

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. BACKGROUND: The long term effect of mammographic service screening is not well established. We aimed to assess the long-term effect of mammographic screening on death from breast cancer, taking into account potential biases from self-selection, changes in breast cancer incidence, and classification of cause of death. METHODS: We compared deaths from breast cancer (...) diagnosed in the 20 years before screening was introduced (1958-77) with those from breast cancer diagnosed in the 20 years after the introduction of screening (1978-97) in two Swedish counties, in 210000 women aged 20-69 years. We also compared deaths from all cancers and from all causes in patients diagnosed with breast cancer in the 20 years before and after screening was introduced. In the analysis, data were stratified into age-groups invited for screening (40-69 years) and not invited (20-39 years

Lancet2003

1933. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.

Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. We aimed to assess frequency and penetrance of BRCA1, BRCA2,and TP53 mutations in women diagnosed with breast cancer aged 30 years or younger, and then correlate this frequency with family history. 17 of 36 familial cases had a BRCA1, BRCA2, or TP53 mutation, compared with three of 63 non-familial cases. The calculated population frequency of TP53 mutations was one in 5000, substantially greater (...) than previous estimates. This finding underlines the importance of accurate elucidation of a family history from young women diagnosed with breast cancer. Establishment of family history could help with development of patient-specific management and tumour surveillance protocols.

Lancet2003

1934. Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort.

Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. OBJECTIVE: To investigate whether size at birth and rate of fetal growth influence the risk of breast cancer in adulthood. DESIGN: Cohort identified from detailed birth records, with 97% follow up. SETTING: Uppsala Academic Hospital, Sweden. PARTICIPANTS: 5358 singleton females born during 1915-29, alive and traced to the 1960 census. MAIN OUTCOME MEASURES: Incidence of breast cancer before (...) (at age <50 years) and after (> or = 50 years) the menopause. RESULTS: Size at birth was positively associated with rates of breast cancer in premenopausal women. In women who weighed > or =4000 g at birth rates of breast cancer were 3.5 times (95% confidence interval 1.3 to 9.3) those in women of similar gestational age who weighed <3000 g at birth. Rates in women in the top fifths of the distributions of birth length and head circumference were 3.4 (1.5 to 7.9) and 4.0 (1.6 to 10.0

BMJ2003 Full Text: Link to full Text with Trip Pro

1935. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. BACKGROUND: Although the efficacy of adjuvant chemotherapy in prolonging survival for women with breast cancer has been well documented, limited population-based information is available on the actual use of chemotherapy. OBJECTIVE: To examine the relationship between age and chemotherapy use. DESIGN: Cohort study. SETTING: New Mexico. PATIENTS: 5101 women 20 years of age (...) or older receiving a diagnosis of stage I, stage II, or stage IIIA breast cancer from 1991 through 1997. MEASUREMENTS: Pattern of chemotherapy use by age; logistic regression analysis to generate the odds and probabilities of receiving chemotherapy; and sensitivity analysis to estimate potential effects of unmeasured confounders. RESULTS: Overall, 29% of women received chemotherapy. The rate of chemotherapy use for women with stage I, stage II, or stage IIIA breast cancer was 11%, 47%, and 68

Annals of Internal Medicine2003 Full Text: Link to full Text with Trip Pro

1936. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study.

Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. BACKGROUND: Clinical decisions about atypical lobular hyperplasia are based on the belief that later invasive breast-cancer risk is equal in both breasts. We aimed to show laterality and subsequent risk implications of invasive breast cancer in women with atypical lobular hyperplasia. METHODS: We did a retrospective cohort study of 252 women who had undergone 261 benign surgical biopsies (...) that showed atypical lobular hyperplasia from 1950 to 1985, as part of the Nashville Breast Studies. Primary outcomes were development of invasive breast cancer and laterality of cancer compared with side of the biopsied breast. FINDINGS: 50 (20%) of 252 women treated by biopsy only developed invasive breast cancer. Relative risk of breast cancer in women with atypical lobular hyperplasia was 3.1 (95% CI 2.3-4.3, p<0.0001). Of these 50 women, the breast with invasive cancer was the same breast

Lancet2003

1937. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer

Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(15). 2003 Authors

Health Technology Assessment (HTA) Database.2003

1938. FDG positron emission tomography for evaluating breast cancer

FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer FDG positron emission tomography for evaluating breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 (...) years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. FDG positron emission tomography for evaluating breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(14). 2003 Authors' objectives This Assessment updates the 2001 TEC Assessment on FDG PET imaging for evaluating breast cancer (Vol. 16, No. 5). This Assessment is organized into 3 parts, as follows: Part I: Initial Staging

Health Technology Assessment (HTA) Database.2003

1939. The role of the taxanes in the management of metastatic breast cancer

The role of the taxanes in the management of metastatic breast cancer The role of the taxanes in the management of metastatic breast cancer The role of the taxanes in the management of metastatic breast cancer Verma S, Trudeau M, Pritchard K, Oliver T, Breast Cancer Disease Site Group CRD summary The authors recommended the use of docetaxel with or without doxorubicin for women who have never previously received anthracyclines, and docetaxel or paclitaxel treatment for those with prior (...) anthracycline use. The poor reporting of review methods and lack of a quality assessment make it difficult to assess the reliability of the authors' conclusions. Authors' objectives To assess the role of taxanes in the management of metastatic breast cancer. In particular, to assess paclitaxel or docetaxel delivered as monotherapy, or in combination with other agents, in patients with no previous anthracycline exposure; and single-agent paclitaxel or docetaxel in patients with prior anthracycline exposure

DARE.2003

1940. Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature

Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature Liberman M, Sampalis F, Mulder D S, Sampalis J S CRD summary This diagnostic review combined studies of scintimammography in different patient populations, and which used different methods of establishing the true diagnosis (...) . The authors concluded that scintimammography would be useful as an additional test in patients with indeterminate mammogram results. The view has a number of methodological weaknesses and the evidence presented does not support the general conclusion. Authors' objectives To assess the performance of scintimammography in the diagnosis of breast cancer. Searching MEDLINE was searched from 1967 to 1999 for articles in English, using the keyword 'scintimammography'. The reference sections of retrieved papers

DARE.2003